{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"5.6","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Time from enrollment to date of first confirmed disease progression or death whichever occurred earlier","dispersionType":"95% Confidence Interval","groups":[{"description":"* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy\n* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab","id":"OG000","title":"Ovarian Cancer (OvC)"},{"description":"One subject enrolled but discontinued before efficacy can be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety.","id":"OG001","title":"Colorectal Cancer"}],"paramType":"MEDIAN","populationDescription":"Participants who received at least one dose of pembrolizumab (galinpepimut-S + pembrolizumab); mITT population. Patients only enrolled in the Ovarian Cancer (OvC) arm. One subject from the Colorectal Cancer (CRC) arm enrolled but discontinued before efficacy can be assessed. The other arms/groups were removed from this study.","reportingStatus":"POSTED","timeFrame":"33 months","title":"Progression-free Survival (PFS) - Kaplan Meier Estimate","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}